Download PDF
Semin Respir Crit Care Med 2017; 38(01): 094-106
DOI: 10.1055/s-0036-1597557
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Acute Pulmonary Embolism after Discharge: Duration of Therapy and Follow-up Testing

Cecilia Becattini
1   Stroke Unit, Department of Vascular Emergency Medicine, University of Perugia, Perugia, Italy
,
Laura Franco
1   Stroke Unit, Department of Vascular Emergency Medicine, University of Perugia, Perugia, Italy
,
Giancarlo Agnelli
1   Stroke Unit, Department of Vascular Emergency Medicine, University of Perugia, Perugia, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
16 February 2017 (online)

    Permissions and Reprints

Abstract

Pulmonary embolism (PE) is a frequent cause of death and serious disability with a risk extending far beyond the acute phase of the disease. Anticoagulant treatment reduces the risk for death and recurrent VTE after a first PE. The optimal duration of anticoagulation after a first episode of PE remains controversial and should be made on an individual basis, balancing the estimated risk for recurrence without anticoagulant treatment against bleeding risk under anticoagulation. Current recommendations on duration of anticoagulation are based on a 3% per year risk of major bleeding expected during long-term warfarin treatment. Anticoagulant therapy should be discontinued after the initial 3 to 6 months in those patients who had the first episode in association with temporary risk factors. After 3 to 6 months of anticoagulant treatment, patients with a first unprovoked event and an estimated low risk for bleeding complications should be evaluated for indefinite treatment on an individualized basis. None of the clinical prediction models for recurrent VTE are able to actually drive duration of anticoagulation. If the favorable safety profile of direct oral anticoagulants from clinical trials would be confirmed in real-life, extension of anticoagulation could be reconsidered in large proportions of patients after an unprovoked PE. The most feared late sequela of PE is chronic thromboembolic pulmonary hypertension. Although there has been progress in both the diagnosis and management of this disease in recent years, further data are needed to provide recommendations regarding long-term follow-up after PE.

Keywords

pulmonary embolism - anticoagulants - dabigatran - rivaroxaban - apixaban - edoxaban
 

  • References

  • 1 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23) (Suppl. 01) I4-I8
    PubMedGoogle Scholar
  • 2 Dentali F, Ageno W, Pomero F, Fenoglio L, Squizzato A, Bonzini M. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thromb Haemost 2016; 115 (2) 399-405
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159 (5) 445-453
    CrossrefPubMedGoogle Scholar
  • 4 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353 (9162): 1386-1389
    CrossrefPubMedGoogle Scholar
  • 5 Pollack CV, Schreiber D, Goldhaber SZ , et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 2011; 57 (6) 700-706
    CrossrefPubMedGoogle Scholar
  • 6 LaMori JC, Shoheiber O, Mody SH, Bookhart BK. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. Clin Ther 2015; 37 (1) 62-70
    CrossrefPubMedGoogle Scholar
  • 7 Yusuf HR, Reyes N, Zhang QC, Okoroh EM, Siddiqi AE, Tsai J. Hospitalizations of adults ≥60 years of age with venous thromboembolism. Clin Appl Thromb Hemost 2014; 20 (2) 136-142
    CrossrefPubMedGoogle Scholar
  • 8 Sanchez O, Trinquart L, Caille V , et al. Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study. Am J Respir Crit Care Med 2010; 181 (2) 168-173
    CrossrefPubMedGoogle Scholar
  • 9 de Bonis S, Rendina D, Vargas G , et al. Predictors of in-hospital and long-term clinical outcome in elderly patients with massive pulmonary embolism receiving thrombolytic therapy. J Am Geriatr Soc 2008; 56 (12) 2273-2277
    CrossrefPubMedGoogle Scholar
  • 10 Klok FA, Zondag W, van Kralingen KW , et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med 2010; 181 (5) 501-506
    CrossrefPubMedGoogle Scholar
  • 11 Meneveau N, Ming LP, Séronde MF , et al. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J 2003; 24 (15) 1447-1454
    CrossrefPubMedGoogle Scholar
  • 12 Meneveau N, Ider O, Seronde MF , et al. Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism. Eur Heart J 2013; 34 (9) 693-701
    CrossrefPubMedGoogle Scholar
  • 13 Kearon C, Akl EA, Ornelas J , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (2) 315-352
    CrossrefPubMedGoogle Scholar
  • 14 Konstantinides SV, Torbicki A, Agnelli G , et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (43) 3033-3069 , 3069a–3069k
    CrossrefPubMedGoogle Scholar
  • 15 Jaff MR, McMurtry MS, Archer SL , et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123 (16) 1788-1830
    CrossrefPubMedGoogle Scholar
  • 16 Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379 (9828): 1835-1846
    CrossrefPubMedGoogle Scholar
  • 17 Hull R, Delmore T, Genton E , et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301 (16) 855-858
    CrossrefPubMedGoogle Scholar
  • 18 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340 (8824): 873-876
    PubMedGoogle Scholar
  • 19 Levine MN, Hirsh J, Gent M , et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74 (2) 606-611
    PubMedGoogle Scholar
  • 20 Schulman S, Rhedin AS, Lindmarker P , et al; Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332 (25) 1661-1665
    CrossrefPubMedGoogle Scholar
  • 21 Boutitie F, Pinede L, Schulman S , et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011; 342: d3036
    CrossrefPubMedGoogle Scholar
  • 22 Kearon C, Akl EA, Comerota AJ , et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012; 141: e419S-e494S
    CrossrefPubMedGoogle Scholar
  • 23 Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med 2010; 363 (3) 266-274
    CrossrefPubMedGoogle Scholar
  • 24 van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (3) 320-328
    CrossrefPubMedGoogle Scholar
  • 25 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e44S-e88S
    CrossrefPubMedGoogle Scholar
  • 26 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31 (3) 326-343
    CrossrefPubMedGoogle Scholar
  • 27 Schulman S, Kearon C, Kakkar AK , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 28 Schulman S, Kakkar AK, Goldhaber SZ , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (7) 764-772
    CrossrefPubMedGoogle Scholar
  • 29 Büller HR, Prins MH, Lensin AW , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 30 Agnelli G, Buller HR, Cohen A , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9) 799-808
    CrossrefPubMedGoogle Scholar
  • 31 Büller HR, Décousus H, Grosso MA , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 32 Prins MH, Lensing AWA, Bauersachs R , et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11 (1) 21
    CrossrefPubMedGoogle Scholar
  • 33 Goldhaber SZ, Schellong S, Kakkar A , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost 2016; 116 (4) 714-721
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
    CrossrefPubMedGoogle Scholar
  • 35 Vedovati MC, Becattini C, Germini F, Agnelli G. Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis. Int J Cardiol 2014; 177 (2) 601-603
    CrossrefPubMedGoogle Scholar
  • 36 Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev 2015; 12 (12) CD010957
    PubMedGoogle Scholar
  • 37 Prins MH, Bamber L, Cano SJ , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015; 135 (2) 281-288
    CrossrefPubMedGoogle Scholar
  • 38 Prandoni P, Noventa F, Ghirarduzzi A , et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92 (2) 199-205
    CrossrefPubMedGoogle Scholar
  • 39 Eichinger S, Weltermann A, Minar E , et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164 (1) 92-96
    CrossrefPubMedGoogle Scholar
  • 40 Jiménez D, Díaz G, Marín E, Vidal R, Sueiro A, Yusen RD. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost 2006; 95 (3) 562-566
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Agnelli G, Prandoni P, Becattini C , et al; Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139 (1) 19-25
    CrossrefPubMedGoogle Scholar
  • 42 Couturaud F, Sanchez O, Pernod G , et al; PADIS-PE Investigators. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE Randomized Clinical Trial. JAMA 2015; 314 (1) 31-40
    CrossrefPubMedGoogle Scholar
  • 43 Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152 (9) 578-589
    CrossrefPubMedGoogle Scholar
  • 44 Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362 (9383): 523-526
    CrossrefPubMedGoogle Scholar
  • 45 Prandoni P, Lensing AW, Piccioli A , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 46 Taliani MR, Agnelli G, Prandoni P , et al; Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 2003; 1 (8) 1730-1733
    CrossrefPubMedGoogle Scholar
  • 47 Verso M, Agnelli G, Ageno W , et al; MASTER investigators. Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thromb Res 2012; 130 (3) 369-373
    CrossrefPubMedGoogle Scholar
  • 48 Ageno W, Samperiz A, Caballero R , et al; RIETE investigators. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res 2015; 135 (4) 666-672
    CrossrefPubMedGoogle Scholar
  • 49 Eischer L, Eichinger S, Kyrle PA. Age at first venous thromboembolism and risk of recurrence: a prospective cohort study. Medicine (Baltimore) 2009; 88 (6) 366-370
    CrossrefPubMedGoogle Scholar
  • 50 Rodger MA, Kahn SR, Wells PS , et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179 (5) 417-426
    CrossrefPubMedGoogle Scholar
  • 51 Roach RE, Lijfering WM, Rosendaal FR, Cannegieter SC, le Cessie S. Sex difference in risk of second but not of first venous thrombosis: paradox explained. Circulation 2014; 129 (1) 51-56
    CrossrefPubMedGoogle Scholar
  • 52 McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006; 368 (9533): 371-378
    CrossrefPubMedGoogle Scholar
  • 53 Douketis J, Tosetto A, Marcucci M , et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011; 342: d813
    CrossrefPubMedGoogle Scholar
  • 54 Cosmi B, Nijkeuter M, Valentino M, Huisman MV, Barozzi L, Palareti G. Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. Intern Emerg Med 2011; 6 (6) 521-528
    CrossrefPubMedGoogle Scholar
  • 55 Pesavento R, Filippi L, Pagnan A , et al; PROVE Investigators Group. Unexpectedly high recanalization rate in patients with pulmonary embolism treated with anticoagulants alone. Am J Respir Crit Care Med 2014; 189 (10) 1277-1279
    CrossrefPubMedGoogle Scholar
  • 56 Golpe R, de Llano LA, Castro-Añón O, Vázquez-Caruncho M, González-Juanatey C, Fariñas MC. Long-term outcome of patients with persistent vascular obstruction on computed tomography pulmonary angiography 6 months after acute pulmonary embolism. Acta Radiol 2012; 53 (7) 728-731
    CrossrefPubMedGoogle Scholar
  • 57 den Exter PL, van Es J, Kroft LJ , et al; Prometheus Follow-Up Investigators. Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism. Thromb Haemost 2015; 114 (1) 26-34
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Palareti G, Cosmi B, Legnani C , et al; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355 (17) 1780-1789
    CrossrefPubMedGoogle Scholar
  • 59 Bruinstroop E, Klok FA, Van De Ree MA, Oosterwijk FL, Huisman MV. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 2009; 7 (4) 611-618
    CrossrefPubMedGoogle Scholar
  • 60 Kearon C, Spencer FA, O'Keeffe D , et al; D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 2015; 162 (1) 27-34
    CrossrefPubMedGoogle Scholar
  • 61 Palareti G, Cosmi B, Legnani C , et al; DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 2014; 124 (2) 196-203
    CrossrefPubMedGoogle Scholar
  • 62 Palareti G, Cosmi B, Antonucci E , et al; DULCIS investigators. Duration of anticoagulation after isolated pulmonary embolism. Eur Respir J 2016; 47 (5) 1429-1435
    CrossrefPubMedGoogle Scholar
  • 63 Rodger MA. Clinical decision rule validation study to predict low recurrent risk in patients with unprovoked venous thromboembolism. 2016 . Available at: https://clinicaltrials.gov/show/NCT00967304
    PubMedGoogle Scholar
  • 64 Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121 (14) 1630-1636
    CrossrefPubMedGoogle Scholar
  • 65 Eichinger S, Heinze G, Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc 2014; 3 (1) e000467
    CrossrefPubMedGoogle Scholar
  • 66 Tritschler T, Méan M, Limacher A, Rodondi N, Aujesky D. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model. Blood 2015; 126 (16) 1949-1951
    CrossrefPubMedGoogle Scholar
  • 67 Marcucci M, Iorio A, Douketis JD , et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. J Thromb Haemost 2015; 13 (5) 775-781
    CrossrefPubMedGoogle Scholar
  • 68 Cost-effectiveness of tailoring anticoagulant therapy by a VTE recurrence prediction model in patients with venous thromboembolism as compared to care-as-usual: The VISTA study. 2016 . Available at: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2680
    PubMedGoogle Scholar
  • 69 Tosetto A, Iorio A, Marcucci M , et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10 (6) 1019-1025
    CrossrefPubMedGoogle Scholar
  • 70 Ensor J, Riley RD, Moore D, Snell KI, Bayliss S, Fitzmaurice D. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open 2016; 6 (5) e011190
    CrossrefPubMedGoogle Scholar
  • 71 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139 (11) 893-900
    CrossrefPubMedGoogle Scholar
  • 72 Prandoni P, Trujillo-Santos J, Sánchez-Cantalejo E , et al; RIETE Group. Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2010; 8 (11) 2575-2577
    CrossrefPubMedGoogle Scholar
  • 73 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105 (2) 91-99
    CrossrefPubMedGoogle Scholar
  • 74 Kuijer PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159 (5) 457-460
    CrossrefPubMedGoogle Scholar
  • 75 Gage BF, Yan Y, Milligan PE , et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151 (3) 713-719
    CrossrefPubMedGoogle Scholar
  • 76 Ruíz-Giménez N, Suárez C, González R , et al; RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (1) 26-31
    Article in Thieme ConnectPubMedGoogle Scholar
  • 77 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (5) 1093-1100
    CrossrefPubMedGoogle Scholar
  • 78 Fang MC, Go AS, Chang Y , et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58 (4) 395-401
    CrossrefPubMedGoogle Scholar
  • 79 Klok FA, Niemann C, Dellas C, Hasenfuß G, Konstantinides S, Lankeit M. Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. J Thromb Thrombolysis 2016; 41 (2) 312-320
    CrossrefPubMedGoogle Scholar
  • 80 Riva N, Dentali F, Permunian ET, Ageno W. Major bleeding and case fatality rate with the direct oral anticoagulants in orthopedic surgery: a systematic review and meta-analysis. Semin Thromb Hemost 2016; 42 (1) 42-54
    Article in Thieme ConnectPubMedGoogle Scholar
  • 81 Kline JA, Jimenez D, Courtney DM , et al. Comparison of four bleeding risk scores to identify rivaroxaban-treated patients with venous thromboembolism at low risk for major bleeding. Acad Emerg Med 2016; 23 (2) 144-150
    CrossrefPubMedGoogle Scholar
  • 82 Di Nisio M, Ageno W, Rutjes AWS, Pap AF, Büller HR. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thromb Haemost 2016; 115 (2) 424-432
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Klok FA, Hösel V, Clemens A , et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016; ERJ-00280-2016
    PubMedGoogle Scholar
  • 84 Schulman S, Kearon C, Kakkar AK , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (8) 709-718
    CrossrefPubMedGoogle Scholar
  • 85 Bauersachs R, Berkowitz SD, Brenner B , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 86 Agnelli G, Buller HR, Cohen A , et al; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (8) 699-708
    CrossrefPubMedGoogle Scholar
  • 87 Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 2014; 48 (5) 565-575
    CrossrefPubMedGoogle Scholar
  • 88 Raskob G, Ageno W, Cohen AT , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 2016; 3 (5) e228-e236
    PubMedGoogle Scholar
  • 89 Ridker PM, Goldhaber SZ, Danielson E , et al; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348 (15) 1425-1434
    CrossrefPubMedGoogle Scholar
  • 90 Kearon C, Ginsberg JS, Kovacs MJ , et al; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349 (7) 631-639
    CrossrefPubMedGoogle Scholar
  • 91 Becattini C, Agnelli G, Schenone A , et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
    CrossrefPubMedGoogle Scholar
  • 92 Brighton TA, Eikelboom JW, Mann K , et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367 (21) 1979-1987
    Google Scholar
  • 93 Simes J, Becattini C, Agnelli G , et al; INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014; 130 (13) 1062-1071
    CrossrefPubMedGoogle Scholar
  • 94 Weitz JI, Bauersachs R, Beyer-Westendorf J , et al; EINSTEIN CHOICE Investigators. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost 2015; 114 (3) 645-650
    Article in Thieme ConnectPubMedGoogle Scholar
  • 95 Andreozzi GM, Bignamini AA, Davì G , et al; SURVET Study Investigators. Sulodexide for the prevention of recurrent venous thromboembolism: the Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation 2015; 132 (20) 1891-1897
    PubMedGoogle Scholar
  • 96 Pai M, Evans NS, Shah SJ, Green D, Cook D, Crowther MA. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2011; 128 (5) 422-430
    CrossrefPubMedGoogle Scholar
  • 97 Rahimi K, Bhala N, Kamphuisen P , et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012; 9 (9) e1001310
    CrossrefPubMedGoogle Scholar
  • 98 Biere-Rafi S, Hutten BA, Squizzato A , et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 2013; 34 (24) 1800-1806
    CrossrefPubMedGoogle Scholar
  • 99 Schmidt M, Cannegieter SC, Johannesdottir SA, Dekkers OM, Horváth-Puhó E, Sørensen HT. Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study. J Thromb Haemost 2014; 12 (8) 1207-1215
    CrossrefPubMedGoogle Scholar
  • 100 Wells PS, Gebel M, Prins MH, Davidson BL, Lensing AWA. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. Thromb J 2014; 12: 26
    CrossrefPubMedGoogle Scholar
  • 101 Lee AY, Levine MN, Baker RI , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2) 146-153
    CrossrefPubMedGoogle Scholar
  • 102 Lee AY, Kamphuisen PW, Meyer G , et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (7) 677-686
    CrossrefPubMedGoogle Scholar
  • 103 Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136 (3) 582-589
    CrossrefPubMedGoogle Scholar
  • 104 Francis CW, Kessler CM, Goldhaber SZ , et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015; 13 (6) 1028-1035
    CrossrefPubMedGoogle Scholar
  • 105 Napolitano M, Saccullo G, Malato A , et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol 2014; 32 (32) 3607-3612
    CrossrefPubMedGoogle Scholar
  • 106 Louzada ML, Carrier M, Lazo-Langner A , et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 (4) 448-454
    CrossrefPubMedGoogle Scholar
  • 107 Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147 (2) 475-483
    CrossrefPubMedGoogle Scholar
  • 108 Prins MH, Lensing AWA, Brighton TA , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (1) e37-e46
    PubMedGoogle Scholar
  • 109 van Es N, Di Nisio M, Bleker SM , et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015; 114 (6) 1268-1276
    Article in Thieme ConnectPubMedGoogle Scholar
  • 110 Castellucci LA, Cameron C, Le Gal G , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013; 347: f5133
    CrossrefPubMedGoogle Scholar
  • 111 Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013; 122 (5) 817-824
    CrossrefPubMedGoogle Scholar
  • 112 Cohn DM, Vansenne F, de Borgie CA, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev 2012; 12: CD007069
    PubMedGoogle Scholar
  • 113 Schulman S, Eriksson H, Goldhaber SZ , et al. Influence of thrombophilia on the efficacy of dabigatran versus warfarin for the extended treatment of acute venous thromboembolism in RE-MEDY. Blood 2014; 124 (21) 1544 [ Abstract]
    PubMedGoogle Scholar
  • 114 Carrier M, Righini M, Wells PS , et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost 2010; 8 (8) 1716-1722
    CrossrefPubMedGoogle Scholar
  • 115 O'Connell C, Razavi P, Ghalichi M , et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost 2011; 9 (2) 305-311
    CrossrefPubMedGoogle Scholar
  • 116 Yoo HH, Queluz TH, El Dib R. Anticoagulant treatment for subsegmental pulmonary embolism. Cochrane Database Syst Rev 2016; 1 (1) CD010222
    PubMedGoogle Scholar
  • 117 Ghazvinian R, Gottsäter A, Elf J. Is it safe to withhold long-term anticoagulation therapy in patients with small pulmonary emboli diagnosed by SPECT scintigraphy?. Thromb J 2016; 14: 12
    CrossrefPubMedGoogle Scholar
  • 118 Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Konstantinides S. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev 2014; 28 (6) 221-226
    CrossrefPubMedGoogle Scholar
  • 119 Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med 2014; 2 (7) 573-582
    CrossrefPubMedGoogle Scholar
  • 120 Klok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 2010; 95 (6) 970-975
    CrossrefPubMedGoogle Scholar
  • 121 Klok FA, Surie S, Kempf T , et al. A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thromb Res 2011; 128 (1) 21-26
    CrossrefPubMedGoogle Scholar
  • 122 Konstantinides SV, Barco S, Rosenkranz S , et al. Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. J Thromb Thrombolysis 2016; 42 (4) 600-609
    CrossrefPubMedGoogle Scholar